文献速递细菌感染、耐药与抗菌药物医院感染防控

人工智能改善细菌感染管理决策:一项叙述性综述

Artificial intelligence for improving decision-making in bacterial infection management: a narrative review.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该综述检索PubMed、Google Scholar、bioRxiv和arXiv至2025年3月,梳理AI驱动的临床决策支持系统在细菌感染预防、诊断、抗生素处方及治疗个体化中的应用。多数研究采用低复杂度模型处理结构化电子健康记录数据,部分在诊断和处方任务上达到临床医生水平,但AI-CDSS仍难以融入临床环境,面临任务范围窄、未考虑工作流程和缺乏评估框架等挑战。作者呼吁转向更自适应和整体的开发方法。

要点

  • AI-CDSS多采用低复杂度模型,在结构化EHR数据上表现良好,部分达到临床医生水平。
  • AI-CDSS融入临床面临任务范围窄、未考虑利益相关者工作流程和缺乏评估框架等挑战。
  • 需转向更自适应和整体的方法,开发能建模感染动态的综合性AI平台以改善抗生素管理。

核心结论

  • 需要将CDSS开发转向更自适应和整体的方法,以认识感染管理中决策过程的连续性。
  • 能建模感染动态的综合性AI平台可改善抗生素管理并帮助应对抗微生物耐药这一全球卫生紧急事件。

研究设计与样本

  • 叙述性综述,检索PubMed、Google Scholar、bioRxiv和arXiv至2025年3月,结合机器学习、决策和细菌感染关键词。

主要发现

  • AI-CDSS研究越来越多利用多模态电子健康记录数据,多数采用低复杂度模型,在结构化数据上表现良好,尤其在有有效特征工程支持时。
  • 部分AI驱动系统在解决诊断和处方任务上达到临床医生水平,但AI-CDSS在很大程度上未能融入临床环境。
  • AI-CDSS的采用面临挑战,涉及 defined medical task 范围窄、未考虑利益相关者工作流程以及缺乏适当评估框架。

临床怎么用

  • 临床应关注AI-CDSS在细菌感染管理中的潜在优势,但需注意其融入临床的挑战,推动更自适应和整体的开发方法。

局限性

  • AI-CDSS的采用面临与 defined medical task 范围窄、未考虑利益相关者工作流程和缺乏适当评估框架相关的挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Development of clinical decision support systems (CDSS) has been ongoing for over 60 years, more recently leveraging technologies such as artificial intelligence (AI) and machine learning (ML). Intelligent CDSS addressing different stages of the infection management process offer potential advantages in interpreting complex data and guiding clinical decision-making. OBJECTIVES: We outline the current applications of AI-driven CDSS across the continuum of bacterial infection management, from prevention and diagnosis to antibiotic prescribing and treatment individualization. We discuss the main limitations hindering their translation into clinical practice, as well as opportunities to improve their development to better meet clinical needs. METHODS: References for this review were identified through searches of PubMed, Google Scholar, bioRxiv and arXiv up to March 2025 by use of a combination of ML, decision-making and bacterial infection keywords. KEY FINDINGS: AI-CDSS studies increasingly leverage multimodal electronic health record (EHR) data, with most adopting lower-complexity models that perform well on structured data, particularly when supported by effective feature engineering. Despite efforts to develop accurate AI-driven systems, some of which achieve clinician-level accuracy in solving diagnostic and prescribing tasks, AI-CDSS have largely failed to integrate into clinical settings. Their adoption faces challenges related to the narrow scope of the defined medical task, failure to consider stakeholder workflow and lack of proper evaluation frameworks. CONCLUSION: There is a need to shift CDSS development towards a more adaptive and holistic approach that recognizes the continuous nature of the decision-making process in infection management. Comprehensive AI-powered platforms that can model infection dynamics could improve antibiotic stewardship and help tackle the global health emergency of antimicrobial resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Talianu A, Fraser-Krauss O, Bolton W, et al. Artificial intelligence for improving decision-making in bacterial infection management: a narrative review. J Antimicrob Chemother. 2026. PMID: 41424120. doi:10.1093/jac/dkaf470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。